Author
Abstract
Solvency II splits life insurance risk into seven risk classes consisting of three biometric risks (mortality risk, longevity risk, and disability/morbidity risk) and four nonbiometric risks (lapse risk, expense risk, revision risk, and catastrophe risk). The best estimate liabilities for the biometric risks are valued with biometric life tables (mortality and disability tables), while those of the nonbiometric risks require alternative valuation methods. The present study is restricted to biometric risks encountered in traditional single-life insurance contracts with multiple causes of decrement. Based on the results of quantitative impact studies, process risk was deemed to be not significant enough to warrant an explicit calculation. It was therefore assumed to be implicitly included in the systematic/parameter risk, resulting in a less complex standard formula. For the purpose of internal models and improved risk management, it appears important to capture separately or simultaneously all risk components of biometric risks. Besides its being of interest for its own sake, this leads to a better understanding of the standard approach and its application extent. Based on a total balance sheet approach we express the liability risk solvency capital of an insurance portfolio as value-at-risk and conditional value-at-risk of the prospective liability risk understood as random present value of future cash flows at a given time. The proposed approach is then applied to determine the biometric solvency capital for a portfolio of general life contracts. Using the conditional mean and variance of a portfolio’s prospective liability risk and a gamma distribution approximation we obtain simple solvency capital formulas as well as corresponding solvency capital ratios. To account for the possibility of systematic/parameter risk, we propose either to shift the biometric life tables or to apply a stochastic biometric model, which allows for random biometric rates. A numerical illustration for a cohort of immediate life annuities in arrears reveals the importance of process risk in the assessment of longevity risk solvency capital.
Suggested Citation
Werner Hürlimann, 2010.
"Biometric Solvency Risk for Portfolios of General Life Contracts. I. The Single-Life Multiple Decrement Case,"
North American Actuarial Journal, Taylor & Francis Journals, vol. 14(4), pages 400-419.
Handle:
RePEc:taf:uaajxx:v:14:y:2010:i:4:p:400-419
DOI: 10.1080/10920277.2010.10597598
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:taf:uaajxx:v:14:y:2010:i:4:p:400-419. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Chris Longhurst (email available below). General contact details of provider: http://www.tandfonline.com/uaaj .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.